论文部分内容阅读
目的评价利奈唑胺和磷霉素联用对临床分离60株甲氧西林耐药的金黄色葡萄球菌(MRSA)的体外抗菌活性。方法用棋盘法设计,微量肉汤稀释法测定不同浓度组合的抗菌药物对60株临床分离MRSA最低抑菌浓度,并计算部分抑菌浓度(FIC)指数判定联合效应。测定利奈唑胺与磷霉素联用或单用对2株MRSA临床分离菌的体外杀菌曲线。结果利奈唑胺与磷霉素联合用药后对60株MRSA临床分菌株的MIC50、MIC90较单药组降低。利奈唑胺与磷霉素联合应用对60株MRSA以协同作用为主(71.67%)。联合用药的杀菌曲线的细菌数量较单药相比降低>2 log10CFU·m L-1,显示协同效应。结论利奈唑胺与磷霉素联合用药在体外对MRSA以协同作用为主,杀菌曲线也显示联合用药有协同效应。
Objective To evaluate the in vitro antibacterial activity of linezolid combined with fosfomycin against 60 strains of methicillin-resistant Staphylococcus aureus (MRSA). Methods The chessboard method was used to determine the minimum inhibitory concentrations (MICs) of MRSA in 60 clinical isolates of antibacterials with different concentrations of antibacterials by the method of micro broth dilution. The combined effects of partial antibacterial concentration (FIC) index were also determined. In vitro bactericidal curves of linezolid and fosfomycin in clinical isolates of two strains of MRSA were determined. Results The MIC50 and MIC90 of 60 strains of clinical isolates of MRSA after linezolid and fosfomycin were lower than those of single drug group. Linezolid and fosfomycin in combination with 60 strains of MRSA synergistic effect (71.67%). The bactericidal curve of combination therapy showed a> 2 log10CFU · m L-1 decrease in the number of bacteria compared with the single drug, showing a synergistic effect. Conclusions The combination of linezolid and fosfomycin is the main synergistic effect on MRSA in vitro. The bactericidal curve also shows the synergistic effect of combination therapy.